Note: This variant has not been sufficiently evaluated by a GET-Evidence editor.
To be considered sufficiently evaluated a variant must have both "variant evidence" and "clinical importance" scores filled in.
Please help improve GET-Evidence by evaluating evidence for this variant!
Insufficiently evaluated pharmacogenetic
(The "insufficiently evaluated" qualifier is assigned automatically based on the above evidence and importance scores.)
Summary of published research, and additional commentary
Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N,
Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A. Association of the
CYP1B1*3 allele with survival in patients with prostate cancer receiving
docetaxel. Mol Cancer Ther. 2008 Jan;7(1):19-26. doi:
10.1158/1535-7163.MCT-07-0557. Epub 2008 Jan 9. PubMed PMID: 18187806.
Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2
polymorphism markedly affects the pharmacokinetics of atorvastatin and
rosuvastatin. Clin Pharmacol Ther. 2009 Aug;86(2):197-203. Epub 2009 May 27.
PubMed PMID: 19474787.